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The discoidin domain receptors, DDR1 and DDR2,
are constitutively dimeric receptor tyrosine kinases
that are activated by triple-helical collagen. Aberrant
DDR signaling contributes to several human patholo-
gies, including many cancers. We have generated
monoclonal antibodies (mAbs) that inhibit DDR1
signaling without interfering with collagen binding.
The crystal structure of the monomeric DDR1 extra-
cellular region bound to the Fab fragment of mAb
3E3 reveals that the collagen-binding discoidin (DS)
domain is tightly associated with the following
DS-like domain, which contains the epitopes of all
mAbs. A conserved surface patch in the DS domain
outside the collagen-binding site is shown to be
required for signaling. Thus, the active conformation
of the DDR1 dimer involves collagen-induced
contacts between the DS domains, in addition to
the previously identified association of transmem-
brane helices. The mAbs likely inhibit signaling by
sterically blocking the extracellular association of
DDR1 subunits.
INTRODUCTION
Receptor tyrosine kinases (RTKs) control many fundamental
cellular processes, such as cell proliferation, differentiation,
migration, and metabolism (Lemmon and Schlessinger, 2010).
RTK activity is normally tightly controlled, and dysregulation of
RTK activity is associated with many human cancers and other
pathologies. Ligand binding to the extracellular region of RTKs
leads to autophosphorylation of their cytoplasmic kinase
domains, creating docking sites for effectors of downstream
signaling. The two major strategies for controlling unwanted
RTK activity in human patients are inhibition by monoclonal anti-
bodies (mAbs) directed against their extracellular regions or by
small molecules targeting the kinase active site (Adams and
Weiner, 2005; Gschwind et al., 2004).688 Structure 20, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rightsThe discoidin domain receptors, DDR1 and DDR2, are RTKs
that are activated by several types of triple-helical collagen,
a major component of the animal extracellular matrix (Leitinger,
2011; Shrivastava et al., 1997; Vogel et al., 1997). The DDRs
are widely expressed in mammalian tissues and have important
roles in embryo development and human disease (Vogel et al.,
2006). For example, DDR1 is essential for mammary gland devel-
opment (Vogel et al., 2001), and DDR2 is essential for the growth
of long bones (Labrador et al., 2001). DDR2mutations in humans
cause a rare, severe form of dwarfism (Ali et al., 2010; Bargal
et al., 2009). The DDRs are also implicated in cancer, fibrotic
diseases, atherosclerosis, and arthritis (Vogel et al., 2006).
Mechanistically, the DDRs have several features that distinguish
them from other RTKs. Compared with the rapid response of
typical RTKs to their soluble ligands (e.g., growth factors),
collagen-induced DDR autophosphorylation is slow and sus-
tained (Shrivastava et al., 1997; Vogel et al., 1997). Furthermore,
Src kinase plays an essential role in DDR activation (Ikeda et al.,
2002).
Both DDRs are composed of an N-terminal discoidin (DS)
domain (Baumgartner et al., 1998), followed by a predicted
DS-like domain (our unpublished results; Lemmon and Schles-
singer, 2010), an extracellular juxtamembrane (JM) region,
a transmembrane (TM) helix, a large cytosolic JM region, and
a C-terminal tyrosine kinase domain. Collagen binds to the DS
domain, and the structural determinants of the DDR-collagen
interaction have been extensively studied (Carafoli et al., 2009;
Ichikawa et al., 2007; Konitsiotis et al., 2008; Leitinger, 2003;
Xu et al., 2011). The remainder of the extracellular region has
not been characterized structurally or functionally.
How collagen binding results in DDR activation is amajor unre-
solved question. DDR1 can be activated by short collagen-like
peptides, showing that DDR clustering by multivalent collagen
assemblies (e.g., fibrils) is not essential for activation (Konitsiotis
et al., 2008). The DDRs are constitutive dimers at the cell surface,
and residues within the TM helix are required for signaling
(Noordeen et al., 2006). In fact, a comprehensive analysis has
shown that the DDRs have the highest propensity of TM helix
self-interactions in the entire RTK superfamily (Finger et al.,
2009). Therefore, the conformational changes resulting from
collagen binding are likely to occur in the context of a stable
DDR dimer. Our crystal structure of a DDR2DS-collagen peptidereserved
Figure 1. The Anti-DDR1 mAbs Block Collagen-Induced DDR1
Phosphorylation
DDR1b was transiently expressed in HEK293 cells, and the cells were stimu-
lated with 10 mg/ml collagen I in the absence or presence of 10 mg/ml of the
indicated anti-DDR1 mAbs. Aliquots of cell lysates were analyzed by SDS-
PAGE and western blotting. The blots were probed with anti-phosphotyrosine
(anti-PY) mAb 4G10 (upper blot) and reprobed with anti-DDR1 Ab (lower blot).
Control, mouse IgG1 isotype control Ab. The experiment was performed three
times with similar results.
See also Figure S1.
Figure 2. The Anti-DDR1 mAbs Bind to the DS-Like Domain and Do
Not Inhibit Ligand Binding
(A) ELISA showing binding of the indicated anti-DDR1 mAbs to recombinant
DDR proteins immobilized on 96-well plates. Shown is a representative of
three independent experiments, each performed in duplicate.
(B) Solid-phase binding assay with recombinant DDR1-Fc protein added to
96-well plates coated with either casein or collagen peptide III-23 (Xu et al.,
2011). DDR1-Fc was preincubated with the indicated anti-DDR1 mAbs before
addition to the wells. Bound DDR1-Fc was detected with anti-human Fc Ab
and was measured as absorbance at 492 nm. Shown is a representative of
three independent experiments, each performed in triplicate. The error bars
indicate the sample standard deviation (n = 3).
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Crystal Structure of a DDR1-Fab Complexcomplex (Carafoli et al., 2009) revealed a 1:1 complex and did
not clarify how collagen binding affects the conformation of the
DDR dimer. Here, we report the functional characterization of
a set of inhibitory anti-DDR1 mAbs and the crystallization of
the almost complete extracellular region of DDR1 bound to
a mAb Fab fragment. The crystal structure led to the discovery
of DDR1 residues that are required for signaling, even though
they are not part of the known collagen-binding site. These
results provide insight into the process of DDR1 activation.
RESULTS
Generation and Characterization of Anti-DDR1 mAbs
We immunized mice with a recombinant protein spanning the
entire extracellular region of human DDR1 and obtained seven
anti-DDR1 mAbs. All seven mAbs were found to inhibit the
collagen-induced autophosphorylation of DDR1 expressed in
HEK293 cells (Figure 1), and this inhibitory activity was retained
by Fab fragments generated from five of the seven mAbs (Fig-
ure S1 available online). Dose-dependent inhibition experiments
revealed no substantial differences in activity among the mAbs,
which all reduced DDR1 phosphorylation to background levels
when applied at 2 mg/ml, but were only partially inhibitory at
0.2 mg/ml (data not shown). Similarly, an enzyme-linked immuno-
sorbent assay (ELISA) with the immobilized DDR1 extracellular
region (His-DDR1) showed that all mAbs boundwith comparable
apparent dissociation constants of2 nM (data not shown). In an
ELISA with domain deletion constructs, all sevenmAbs bound to
the membrane-proximal DS-like domain (His-DDS-DDR1), butStructure 20not to the membrane-distal DS domain containing the
collagen-binding site (His-DS-DDR1) (Figure 2A). This result sug-
gested that the inhibitory activity of the mAbs on cells was
unlikely to be the result of a block of collagen binding. Indeed,
when we tested a subset of mAbs in a direct collagen binding
assay, we found that binding of DDR1-Fc to a high-affinity
collagen peptide (III-23) (Xu et al., 2011) was not affected
by the addition of mAbs (Figure 2B). The combined results
demonstrate that the anti-DDR1 mAbs inhibit DDR1 function
by interfering with the signal transduction process resulting
from collagen binding.
Crystal Structure of a DDR1-Fab Complex
For several years, we had attempted unsuccessfully to obtain
diffracting crystals of the extracellular regions of DDR1 or
DDR2. Fab fragments of mAbs have been instrumental in, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 689
Table 1. Crystallographic Statistics of the DDR1-3E3 Fab
Structure
Data Collection Value
Space group C2221
Unit cell dimensions
a, b, c (A˚) 102.51, 251.48, 75.37
a, b, g () 90, 90, 90
Asymmetric unit content 1:1 DDR1-3E3 Fab complex
Solvent content (%) 57
Resolution (A˚) 50–2.8 (2.95–2.80)a
Rmerge 0.079 (0.429)
<I/s(I) > 14.3 (3.8)
Completeness (%) 98.7 (98.9)
Multiplicity 6.0 (6.1)
Refinement
Resolution (A˚) 20–2.8
Reflections 24035
Protein atoms 2700 (DDR1) + 3169 (3E3 Fab)
Solvent atoms 2 Ca2+ + 14 H2O
Rwork/Rfree 0.216/0.286
Rmsd bonds (A˚) 0.007
Rmsd angles () 1.4
Average B-factor (A˚2) 53.6
Ramachandran plot (%)b 91.3/98.1
aValues in parentheses are for the highest resolution shell.
bPercentage of residues in favored and allowed regions (Chen et al.,
2010).
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Crystal Structure of a DDR1-Fab Complexfacilitating the crystallization of many recalcitrant proteins
(Nettleship et al., 2008). We therefore screened the Fab frag-
ments of six anti-DDR1mAbs for complex formation and cocrys-
tallization with the extracellular region of DDR1 (the 1F7 Fab
could not be used because it aggregated in solution). Because
the His-DDR1 construct used for mAb generation included the
JM region that is predicted to be unstructured, we produced
a construct terminating at the predicted C terminus of the DS-
like domain, Asp367. All Fab fragments bound to this shortened
DDR1 construct, as determined by analytical size exclusion
chromatography (data not shown). We obtained crystals of the
DDR1-3E3 Fab complex and determined its structure at a resolu-
tion of 2.8 A˚ (Table 1).
The extracellular region of DDR1 revealed by the crystal struc-
ture is a compact structure measuring approximately 70 3 503
40 A˚ (Figure 3A). The DS and DS-like domains are arranged such
that the long axes of their b-barrels are roughly perpendicular to
each other. There is an extensive interface between the two
domains that buries 1410 A˚2 of solvent-accessible surface (i.e.,
the interface measures 700 A˚2). The domain arrangement in
DDR1 is reminiscent of the tandem DS domains in neuropilins
(Appleton et al., 2007; Vander Kooi et al., 2007), but the second
domain is rotated differently in the two proteins (Figure S2). The
N andC termini of the crystallized DDR1 construct are located on
the same face of the molecule near the interdomain linker. In the
intact receptor, the C terminus of the crystallized construct
would be linked to the TM helix by the 50-residue JM region.690 Structure 20, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rightsThe DDR1 DS domain is very similar to the DDR2 DS domain
(rmsd of 0.61 A˚ for 156 Ca atoms), which was previously crystal-
lized in complex with a collagen-like peptide (Carafoli et al.,
2009). The collagen-binding loops of the DDR1 DS domain,
which are opposite the DS-like domain, have weak electron
density and high temperature factors, suggesting that they are
quite mobile in the absence of the collagen ligand. The 3E3
Fab fragment is bound near the C terminus of the DS-like
domain, distant from the collagen-binding site (for a description
of the epitope, see below).
Structure of the DS-like Domain
As predicted (our unpublished results; Lemmon and Schles-
singer, 2010), the DS-like domain belongs to the coagulation
factor V/VIII type C superfamily. A search with the program
SSM (Krissinel and Henrick, 2004) showed that the DS-like
domain of DDR1 is most closely related to family 32 carbohy-
drate-bindingmodules (CBMs) (Boraston et al., 2004), but a pair-
wise alignment of the DS and DS-like domains of DDR1 gave
only a marginally lower Z-score and a rmsd of 3.0 A˚ for 120
aligned Ca atoms (Figure 3B). To facilitate the comparison of
the DS and DS-like domains, the eight b strands that are
common to both domains have been labeled b1–b8. The DS-
like domain contains five additional strands, labeled ba–be, in
a long insertion between b1 and b2. Both domains are character-
ized by two antiparallel b sheets with jellyroll topology (b1-b2-b7-
b4 sheet and b5-b6-b3-b8 sheet). At one end of the b-barrel (the
‘‘bottom’’) the b2–b3 and b6–b7 loops cross over between the
sheets and create a relatively flat surface. At the other end (the
‘‘top’’), several long and irregular loops protrude from the barrel.
In the DS domain, these loops constitute the collagen-binding
site (Carafoli et al., 2009; Ichikawa et al., 2007; Leitinger, 2003).
In the DS-like domain, they contribute the extra strands ba–be,
two N-linked glycosylation sites (Asn211 and Asn260), and
a calcium-binding site. The calcium ion is coordinated by the
side chains of Asp233 andGlu361, as well as by threemain chain
carbonyl groups; an analogous calcium coordination is seen in
many family 32 CBMs (Boraston et al., 2004). It is noteworthy
that the glycosylation site at Asn211 and the calcium ligands
are strictly conserved in all vertebrate DDRs (Figure S3). A
second ion in the DS-like domain was also modeled as calcium,
but this ion appears to be bound more weakly and may be
a crystal artifact (not shown). The DS-like domain of DDR1
contains three cysteines: Cys303 and Cys348, which form
a deeply buried disulphide bridge linking the adjacent b4 and
b7 strands, and Cys287, which is unpaired and also buried. A
previous study suggested that Cys303 and Cys348 may be
involved in the covalent dimerization of DDR1 (Abdulhussein
et al., 2008). However, the DS-like domain would have to unfold
for these two residues to become available for intermolecular
disulphide bridges. The disulphide-linked dimers seen in cell
lysates in that study therefore are more likely to have resulted
from oxidation following denaturation.
The interface between the DS and DS-like domains of DDR1 is
formed between the bottom of the DS domain, in particular the
b4–b5 and b6–b7 loops, and the long convoluted insertion
between strands b1 and b2 of the DS-like domain (Figure 3C).
A key interface residue is Trp187, which is located in the short
linker between the two domains and which interacts withreserved
Figure 3. Crystal Structure of the DDR1-3E3 Fab Complex
(A) Overall structure. The 3E3 Fab fragment is shown as a surface (tan, light chain; gray, heavy chain), and DDR1 is shown as a cartoon (cyan, DS domain; green,
DS-like domain; and red, collagen-binding loops; Carafoli et al., 2009; orange, disulphide bridges). A calcium ion is shown as a magenta sphere and the two
N-linked glycans are shown as light blue sticks. The N and C termini of the DDR1 construct are indicated. The b strands of the jelly roll in the DS and DS-like
domains are numbered 1–8, and the extra b strands in the DS-like domain are labeled a–e.
(B) Superposition of the DS domain (cyan) and the DS-like domain (green) of DDR1.
(C) Detailed structure of the interface between the DS domain (cyan) and the DS-like domain (green) in DDR1. Selected residues are shown in atomic detail and
labeled. Hydrogen bonds are indicated by dashed lines.
See also Figures S2 and S3.
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Crystal Structure of a DDR1-Fab Complexresidues of both the DS domain (Leu94 and Val160) and the DS-
like domain (Leu191, Leu192, Leu228, and Ala232). With the
exception of Leu192 and Ala232, these residues are strictly
conserved in all vertebrate DDRs (Figure S3). Also conserved is
an ion pair spanning the interface, involving Arg124 of the DS
domain and Asp216 of the DS-like domain. Additional interdo-
main contacts are made between the 134–138 and 245–253
loops (Figure 3C). Even though the shape complementarity of
the domain interface is not particularly high (sc-value of 0.56;
Lawrence and Colman, 1993), its size and the conservation of
key interface residues suggest that the domain arrangement
seen in our structure is stable and representative of DDRs in
general.
DS Domain Residues Required for DDR1 Signaling
The DDRs are believed to be constitutive dimers at the cell
surface (Mihai et al., 2009; Noordeen et al., 2006). Analytical
ultracentrifugation of the crystallized DDR1 ectodomain
construct showed it to be monomeric at concentrations of up
to 6.8 mg/ml (data not shown), in agreement with an earlier result
obtained by size-exclusion chromatography for His-DDR1
(Leitinger, 2003). However, because the high protein concentra-
tion in the crystal might favor a very weak dimer association, we
inspected the crystal lattice for DDR1 dimers. There was only
one plausible dimer. The interface between the two DDR1 mole-Structure 20cules in this dimeric lattice contact is dominated by two identical,
symmetry-related contacts and buries 1580 A˚2 of solvent-
accessible surface with good shape complementarity (sc-value
of 0.64). In each of the symmetry-related contacts, four DS
domain residues—Arg32, Leu99, Leu152, and Tyr183—interact
with Leu247 and Arg248 of the other DDR1molecule (Figure 4A).
The four DS domain residues in the contact are strictly
conserved in DDR1 and DDR2 from several species, whereas
Leu247 and Arg248 are variable (Figure S3). To test whether
these DDR1 regions are required for function, we expressed
three DDR1 mutants (R32E, L152E, and L247E/R248E) in
HEK293 cells and measured their collagen-induced autophos-
phorylation. Flow cytometry showed that the mutants were
expressed at the cell surface similarly to wild-type DDR1
(Figure 4B). Furthermore, SDS-PAGE analysis of the mutants
showed the characteristic two bands corresponding to the
immature (intracellular) and mature (cell surface-expressed) gly-
coforms of the receptor (Noordeen et al., 2006) (Figure 4C). The
L247E/R248E double mutation had no effect on DDR1 activation
(Figure 4C), indicating that the dimeric crystal lattice contact
does not recapitulate a signaling state of the receptor. In sharp
contrast, the R32E and L152E mutations abrogated DDR1 acti-
vation (Figure 4C). This result was unlikely to be due to an effect
on ligand binding, given that the two mutations are distant from
the high-affinity collagen-binding site (Carafoli et al., 2009)., 688–697, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 691
Figure 4. A Conserved Patch in the DS Domain Is Required for DDR1 Signaling
(A) The lattice contact resulting in a symmetric DDR1 dimer (see text). The DDR1molecule on the left is in cyan (DS domain) and green (DS-like domain); the DDR1
molecule on the right is in gray, with the collagen-binding loops (Carafoli et al., 2009) in red. The 2-fold symmetry axis is vertical. Selected residues are shown in
atomic detail (pink, conserved surface patch in the DS domain).
(B) Cell surface expression of mutants. Wild-type DDR1b or the indicated mutants were transiently expressed in HEK293 cells. The cells were stained on ice with
10 mg/ml of anti-DDR1 mAb 7A9 (filled gray histograms) or mouse IgG1 isotype control Ab (black lines) followed by FITC-conjugated goat-anti mouse IgG and
analysis by flow cytometry. The experiment was performed twice with similar results.
(C) Collagen-induced activation ofmutants.Wild-type DDR1b or the indicatedmutants were transiently expressed in HEK293 cells. The cells were stimulatedwith
collagen I at the indicated concentrations (in mg/ml). Aliquots of cell lysates were analyzed by SDS-PAGE and western blotting. The blots were probed with anti-
phosphotyrosine (anti-PY) mAb 4G10 (upper blot) and reprobed with anti-DDR1 Abs (lower blot). The experiment was performed three times with similar results.
(D) Solid-phase binding assay with recombinant DDR1-Fc protein (filled circles, wild-type; open circles, R32E mutant) added to 96-well plates coated with
collagen peptide III-23 (Xu et al., 2011). Bound DDR1-Fc was detected with anti-human Fc Ab and was measured as absorbance at 492 nm. Shown is
a representative of two independent experiments, each performed in duplicate.
Structure
Crystal Structure of a DDR1-Fab ComplexIndeed, collagen-binding experiments with soluble DDR1 R32E
and DDR2 L152E proteins (Figure 4D and data not shown)
confirmed that these mutants are not defective in collagen
binding. These findings demonstrate that the conserved surface
patch in the DS domain containing Arg32 and Leu152 is required
for DDR1 signaling, even though it is not part of the primary
collagen-binding site.
Epitopes of Anti-DDR1 mAbs
The 3E3 epitope is formed from three regions of the DDR1 DS-
like domain, which are discontinuous in sequence but contig-
uous in space: the start of b3 (Ala279, Gln281, and Ala282), the
b6–b7 loop (Ser 335, Pro337, Gly340, Arg341, and Val342),
and the very end of the DS-like domain (Ile365 and Asp367)
(Figure 5). The 3E3 Fab uses predominantly aromatic residues
to recognize this epitope: Thr30, Phe32, Tyr34, Tyr49, and
Leu50 of the light chain; and Ile31, Trp33, Tyr52, Tyr56, and692 Structure 20, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rightsTyr96 of the heavy chain. In total, the DDR1-3E3 interface buries
1390 A˚2 of solvent-accessible surface and has a high shape
complementarity value of 0.68, a typical value for antibody-
antigen complexes (Lawrence and Colman, 1993). The finding
that mAb 3E3 binds close to the C terminus of the DS-like
domain suggests that it may inhibit DDR1 function by preventing
the association of the DS-like domains and/or JM regions in the
signaling DDR1 dimer. The JM region is unlikely to make a major
contribution to 3E3 binding, however, given that the 3E3 Fab and
the truncated DDR1 ectodomain construct used for crystalliza-
tion form a stable complex upon size-exclusion chromatography
(see Experimental Procedures).
To better understand how the anti-DDR1 mAbs inhibit DDR1
function, it was of interest to determine the epitopes of the other
mAbs as well. We therefore made a series of DDR1 mutants,
which targeted all linear and nonconservative human-to-mouse
substitutions in the DS-like domain (Figure S3). These DDR1reserved
Figure 5. Detailed Structure of the DDR1-3E3 Fab Interface
The 3E3 Fab fragment is shown as a semitransparent surface (tan, light chain;
gray, heavy chain), and the DDR1 region interacting with the Fab is shown as
a green cartoon. Selected interface residues are shown in atomic detail and
labeled. Hydrogen bonds are indicated by dashed lines.
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Crystal Structure of a DDR1-Fab Complexmutants were expressed in HEK293 cells, and mAb binding was
measured by flow cytometry (Figure 6A and Figure S4). Mutant
mut7 (R341H/A343G) was consistently expressed at lower levels
than the wild-type protein, suggesting that the mutation may
have compromised the DDR1 structure. All other mutants were
expressed at similar levels to the wild-type protein. Saturating
concentrations of all but one mAbs gave similar fluorescence
profiles for wild-type DDR1. The single exception was 1F10,
which is a different isotype (IgG2b) than the other anti-DDR1
mAbs (IgG1) and therefore may be detected less well by the
secondary Ab.
Four of the DDR1 mutants (mut2, mut3, mut4, and mut7)
showed unperturbed binding of all seven mAbs. The mut1 muta-
tion (203-YLSEAVY to QLSEVMVH) abolished binding of mAbs
3G10, 3H10, and 7A9. The mut6 mutation (M318V/N321A/
N325S) abolished binding of mAbs 1F7 and 1F10. The mut5
mutation (A279T/A282T) reduced binding of mAb 3E3 by
70% (mean fluorescence data in Figure S4). Inspection of the
DDR1-3E3 interface structure (Figure 5) suggests that, in order
to completely disrupt 3E3 binding, Arg341 would have to be
substituted in addition to Ala279 and Ala282. Given that
Arg341 (mut7) interacts with Met318 (mut6), disruption of 3E3
binding is likely to require a combination of mut5-7—that is,
a complete reconfiguring to the mouse structure at the base of
the DS-like domain. Binding of mAb 5D5 was not affected by
any of the mutations, and we assume that the 5D5 epitope simi-
larly is a combination of the linear sequence motifs targeted in
our experiments. In summary, the six inhibitory anti-DDR1
mAbs for which the epitopes could be defined (by eithermutation
or structure determination) bind to two distinct regions of the
DS-like domain that are >50 A˚ away from the collagen-binding
site in the DS domain (Figure 6B).Structure 20DISCUSSION
In this article, we report three major findings that advance the
mechanistic understanding of DDR signaling: First, crystal struc-
ture analysis has revealed that the extracellular region of DDRs
consists of two structurally related domains, a collagen-binding
DS domain and a DS-like domain. Second, we have generated
anti-DDR1 mAbs that inhibit collagen-induced DDR1 activation
by binding to the DS-like domain. Third, we have identified
a conserved surface patch in the DS domain that is distinct
from the collagen-binding site, yet is required for DDR activation.
These results are integrated into a working model of how
collagen binding might alter the extracellular structure of DDRs
and thereby lead to receptor activation.
The N-terminal domain of DDRs has long been recognized as
amember of the DS superfamily (Johnson et al., 1993; Karn et al.,
1993), and its role in collagen binding is understood in atomic
detail (Carafoli et al., 2009; Ichikawa et al., 2007). Our crystal
structure shows that the second DDR domain is a distant relative
of the DS domain, termed the DS-like domain. Tandem repeats
of DS domains occur in a number of secreted and cell surface
proteins (Baumgartner et al., 1998; Kiedzierska et al., 2007). In
the blood coagulation factors V and VIII, the two DS domains
are arranged side by side with limited contacts between them,
so that their top loops can both interact with the same cell
membrane (Adams et al., 2004; Ngo et al., 2008; Shen et al.,
2008). In neuropilin-1 and -2, the two DS domains are related
by a 90 rotation and form a compact structure, as in DDR1
(Appleton et al., 2007; Vander Kooi et al., 2007). This angled
arrangement in DDR1 results in the C terminus of the DS-like
domain emerging near the interdomain linker. The presumably
unstructured JM region of DDR1 linking the DS-like domain to
the TM helix (residues 368–417) contains 12 prolines and
a number of predictedN- andO-linked glycosylation sites. If fully
extended, it would project the DS and DS-like domains of DDR1
150 A˚ from the cell surface. The JM regions of other DDRs are
similarly long, ranging from 32 to 74 residues.
mAbs directed against RTKs are invaluable tools for research
and have been developed into successful therapeutics (Adams
and Weiner, 2005). We have characterized seven anti-DDR1
mAbs that inhibit DDR1 function by binding to two distinct
regions in the DS-like domain. Notably, Fab fragments derived
from these mAbs were equally effective as DDR1 inhibitors. No
mAbs were obtained that bind to the DS domain, possibly
reflecting the higher degree of surface conservation in that
domain (not shown). In agreement with their epitope locations,
the mAbs inhibit DDR1 function without blocking collagen
binding. We think that they do so by preventing the proximity
of the two DS-like domains and the following JM regions in the
collagen-bound, signaling, state of the DDR1 dimer (Noordeen
et al., 2006). Deletion of the DS-like domain or JM region of
DDR1 results in receptors that are not trafficked to the cell
membrane, so the contribution of these regions to signaling
could not be studied (Noordeen et al., 2006). Remarkably,
however, the DS-like domain of DDR2 could be deleted without
abrogating collagen-induced receptor autophosphorylation
(Leitinger, 2003), suggesting that the DS-like domain is not
making any essential contacts in the signaling DDR dimer. This
leaves the collagen-bound DS domain as the most likely site of, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 693
Figure 6. Epitope Mapping of Anti-DDR1 mAbs
(A) Wild-type DDR1b or the indicated mutants were transiently expressed in HEK293 cells. The cells were stained on ice with 10 mg/ml of the indicated anti-DDR1
mAbs or mouse IgG1 isotype control Ab, followed by FITC-conjugated goat-anti mouse IgG and analysis by flow cytometry. Binding of isotype control Ab is
shown by the filled gray histograms. Shown are representative data of at least three experiments for each DDR1 mutant.
(B) Surface representation of DDR1 structure showing the location of mAb epitopes determined by mutation (mut1, blue: 3G10, 3H10, 7A9; mut6, purple: 1F7,
1F10). The 3E3 footprint from the crystal structure is shown in light orange, andmut5 is shown in dark orange. The DS and DS-like domains are in cyan and green,
respectively. The collagen-binding site and conserved surface patch (Arg32, Leu99, Leu152, and Tyr183) are shown in red and light pink, respectively. The
C terminus is indicated.
See also Figure S4.
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Crystal Structure of a DDR1-Fab Complexcontact between the extracellular regions of the two DDR proto-
mers in the signaling dimer.
An analysis of crystal lattice contacts in the DDR1-3E3 Fab
structure led to the fortuitous discovery of functionally important
residues near the base of the DS domain, close to the interface
with the DS-like domain and distant from the collagen-binding
site at the top of the DS domain. The patch formed by these resi-
dues is the largest concentration of conserved surface residues
in the extracellular region of DDRs apart from the collagen-
binding site, consistent with its essential role in signaling. We
think that the conserved patch is involved in mediating protomer
contacts in the signaling DDR dimer, either by forming a direct694 Structure 20, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rightsDS-DS interface or by providing a secondary collagen-binding
site. The latter alternative is more appealing, because it provides
a plausible mechanism whereby collagen could cross-link
two DS domains (analogous to the ‘‘composite binding site’’
model discussed by Carafoli et al., 2009). In solution, the
isolated DDR2 DS domain binds a 28-residue collagen peptide
with 1:1 stoichiometry (Carafoli et al., 2009). However, inspection
of the crystal lattice of this DS-collagen complex reveals that
the conserved patch is involved in a lattice contact with
the N-terminal glycine-proline-hydroxyproline triplets of the
collagen peptide. This intriguing observation may suggest that
the conserved patch in the DS domain indeed has weak affinityreserved
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Crystal Structure of a DDR1-Fab Complexfor collagenous sequences and, therefore, could provide a
secondary collagen-binding site in dimeric, full-length DDR.
Whichever interactions are formed between the DS domains
and the collagen ligand, they are expected to lead to structural
changes within the DDR dimer that are propagated across the
cell membrane to result in DDR autophosphorylation (Noordeen
et al., 2006). Tight coupling of the extracellular conformational
changes to intracellular domain arrangements is difficult to
imagine in the DDRs, given their long, and presumably flexible,
JM regions. Recent studies of the epidermal growth factor
receptor (EGFR) have shown that the conformational coupling
across the cell membrane is looser than commonly believed,
even in a receptor with less extensive JM regions (Lu et al.,
2010; Mi et al., 2011). However, one important difference is
that the TM helices of DDRs have a much higher propensity for
self-interactions than that of EGFR (Finger et al., 2009). We
propose that the TM helices are largely responsible for constitu-
tive DDR dimerization (Noordeen et al., 2006), but that collagen-
induced interactions involving the DS domains are additionally
required for DDR activation.
EXPERIMENTAL PROCEDURES
DNA Constructs and Site-Directed Mutagenesis
All mutations were generated by strand overlap extension PCR using a cDNA
of human DDR1 as a template (Leitinger, 2003). The PCR primers used to
generate these constructs are available on request. The amplified DNAs
were cloned into the mammalian expression vectors pcDNA3.1/Zeo (Invitro-
gen) or pRK5 (BD PharMingen) for expression of full-length proteins, or into
modified pCEP vectors (Kohfeldt et al., 1997) for expression of soluble
proteins. All PCR-derived DNA constructs were verified by sequencing.
Production of Soluble DDR1 Proteins
The following proteins were produced as described elsewhere (Leitinger,
2003): His-DDR1 contains the entire extracellular region of human DDR1
(residues 19–416 of UniProt entry Q08345). His-DDR2 contains the entire
extracellular region of human DDR2 (residues 22–398 of UniProt entry
Q16832). His-DS-DDR1 and His-DDS-DDR1 are deletion constructs based
on His-DDR1. His-DS-DDR1 lacks the DS-like domain (D201–369), and His-
DDS-DDR1 lacks the DS domain (D31–185); both proteins retain the JM
region. DDR1-Fc contains the entire DDR1 extracellular region fused to
a C-terminal human IgG1 Fc sequence (Leitinger, 2003; Xu et al., 2011).
The DDR1 construct for crystallography contains the DS and DS-like
domains of human DDR1 (residues 30–367) fused to a C-terminal His-tag
(AAAHHHHHH). A vector-derived APLA sequence is present at the N terminus
of the mature protein. The protein was produced in human embryonic kidney
HEK293 c18 cells (ATCC). The cells were grown at 37C with 5% CO2 in
Dulbecco’s modified Eagle’s medium/F12 (Invitrogen) containing 10% fetal
bovine serum, 2 mM glutamine, 10 U/ml penicillin, 100 mg/ml streptomycin,
and 250 mg/ml geneticin. The cells were transfected with the pCEP-Pu expres-
sion plasmid using Fugene (Roche Diagnostics) and were selected with
1 mg/ml puromycin (Sigma). Confluent cells in a HYPERFlask (Corning) were
washed twice with PBS and incubated with serum-free medium for 3–4 weeks,
with weekly medium exchanges. The pooled serum-free conditioned medium
was loaded onto a 5-ml HisTrap column (GE Healthcare) using an A¨kta Purifier
(GE Healthcare). The protein was eluted with 500 mM imidazole in PBS,
concentrated using a Vivaspin centrifugal device (Sartorius), and further puri-
fied on a Superdex 200 HR10/30 size-exclusion chromatography column (GE
Healthcare) with Tris-buffered saline (TBS) (25 mM Tris, 150 mM NaCl, and
2 mM KCl [pH 7.4]) as the running buffer.
Generation of Anti-DDR1 Antibodies
To prepare an untagged antigen for immunization, 500 mg of His-DDR1
(Leitinger, 2003) was digested with 25 U EKMax enterokinase (Invitrogen) forStructure 2016 hr at 4C. EKMax was removed with EK-Away resin (Invitrogen) according
to themanufacturer’s protocol. UncleavedHis-DDR1 and the cleaved tagwere
removed with TALON metal affinity beads (Clontech). The untagged DDR1
protein was dialyzed against PBS and concentrated to 2 mg/ml by ultrafiltra-
tion. Mouse anti-DDR1 mAbs were generated by immunizing female BALB/c
mice with the untagged DDR1 protein. Three days after the final boost, one
mouse was sacrificed to obtain splenocytes for hybridoma production by
standard procedures. Hybridoma cell supernatants were screened against
DDR1-Fc and His-DDR1 proteins by ELISA. Reactive hybridoma supernatants
were further screened for recognition of native DDR1 by cell-based ELISA,
using HEK293 cells expressing full-length DDR1. Positive hybridoma cells
were subcloned by limited dilution and screened as above. The isotype
of each mAb was determined by standard methods. All mAbs are of the
IgG1 isotype, with the exception of mAb 1F10, which is IgG2b.
Antibody and Fab Fragment Production
Hybridoma cells were grown at 37C with 5% CO2 in RPMI-1640 medium
(Invitrogen) containing 10% fetal bovine serum, 1 mM sodium pyruvate,
10 U/ml penicillin, 100 mg/ml streptomycin, and 1 mg/ml fungizone (Invitrogen).
The serum concentrationwas gradually reduced to 5% in a final culture volume
of 1 l. The hybridoma cell culture supernatant was loaded onto a 2 3 1-ml
HiTrap rProtein A column (GE Healthcare). The mAbs were eluted with Immu-
nopure gentle elution buffer (Pierce) and dialyzed against TBS. Fab fragments
were generated with a Fab Preparation Kit (Pierce) according to the manufac-
turer’s protocol. Briefly, 8 mg of mAb were incubated overnight at 37C
with activated papain immobilized on agarose resin. The Fc fragment and
undigested mAb were removed using a 1-ml HiTrap rProtein A column (GE
Healthcare), yielding 3 mg of Fab fragment. The Fab fragments used in
cocrystallization experiments were further purified by size-exclusion chroma-
tography on a Superdex 200 HR10/30 column (GE Healthcare) with TBS as the
running buffer.
mAb cDNA Synthesis and Sequencing
Total RNA was prepared from 107 3E3 hybridoma cells using the RNeasy
Mini Kit (QIAGEN). The RNA was reverse-transcribed, and cDNA fragments
encoding the heavy- and light-chain variable regions of the mAb were ampli-
fied using the SuperScript III One-Step RT-PCR system (Invitrogen) and
suitable universal primers (Orlandi et al., 1989). The PCR products were
gel-purified and sequenced using the same primers. The mAb residues are
numbered according to Al-Lazikani et al. (1997).
DDR1 Activation Assay
The assay was performed as described elsewhere (Leitinger, 2003). Briefly,
HEK293 cells were grown in 12-well tissue culture plates and transfected
with 2 mg/well of DDR1 wild-type or mutant plasmid DNA using calcium
phosphate precipitation. Twenty-four hours after transfection, the cells were
incubated with serum-free medium for 16 hr. Cells were then stimulated with
10–50 mg/ml acid-soluble rat tail collagen I (Sigma) for 90 min at 37C before
being lysed. In the inhibition experiments, anti-DDR1 mAbs or their Fab frag-
ments were added together with collagen I, without prior incubation. Aliquots
of the cell lysates were subjected to SDS-PAGE and blotted onto nitrocellulose
membranes. The blots were first probed with a mouse anti-phosphotyrosine
mAb (clone 4G10, Upstate Biotechnology) followed by a horseradish peroxi-
dase-conjugated sheep anti-mouse Ig (Amersham Biosciences). Detection
was done by Enhanced Chemiluminescence Plus (Amersham Biosciences)
using an Ettan DIGE Imager (GE Healthcare). To reprobe the blots, the
membranes were treated with Ab stripping solution (Alpha Diagnostic Interna-
tional), followed by incubation with rabbit anti-DDR1 Ab (SC-532, Santa Cruz
Biotechnology), and finally goat horseradish peroxidase-conjugated anti-
rabbit Ig (P0448, DAKO).
ELISA and Solid Phase Binding Assays
Recombinant DDR proteins, diluted to 10 mg/ml in 50 mM Tris and 100 mM
NaCl (pH 8.5), were coated in 50-ml aliquots onto Maxisorp 96-well plates
(Nalgene NUNC) overnight at room temperature. The wells were blocked
with 150 ml of incubation buffer (PBS containing 40 mg/ml bovine milk k-casein
[Sigma] and 0.05% Tween-20) for 1 hr at room temperature. Anti-DDR1 mAbs
were added at 30 mg/ml in 50-ml aliquots and were incubated for 1.5 hr at room, 688–697, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 695
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Crystal Structure of a DDR1-Fab Complextemperature. The wells were washed six times with incubation buffer, followed
by the addition of horseradish peroxidase-conjugated sheep anti-mouse Ig
(Amersham Biosciences, 1:1000 dilution in incubation buffer) for 1.5 hr at
room temperature. After six washes as above, bound mAbs were detected
with 75 ml/well of 500 mg/ml o-phenylenediamine dihydrochloride (Sigma-
Aldrich) in 50 mM citrate-phosphate (pH 5.0). The reaction was stopped after
3–5 min with 50 ml/well of 3 M H2SO4. The absorbance at 492 nm was
measured using a Sunrise 96-well plate reader (Tecan).
To measure DDR1 binding to the collagen-derived peptide III-23, Immulon 2
HB 96-well plates (Fisher Scientific) were coated overnight at room tempera-
ture with 10 mg/ml III-23 in 10 mM acetic acid (Xu et al., 2011). The wells
were then blocked in incubation buffer as described above. DDR1-Fc proteins
were added in various concentrations and incubated for 3 hr. In the inhibition
experiments, the DDR1-Fc protein was incubated with anti-DDR1 mAbs for
30 min at room temperature before being added to the wells. After six washes
with incubation buffer, bound DDR1-Fc was detected with horseradish perox-
idase-conjugated goat anti-human Fc (Jackson ImmunoResearch Laborato-
ries, 1:3333 dilution), added for 1 hr at room temperature. The assay was
completed as described above.
Flow Cytometry
HEK293 cells were grown in 6-well plates and transfected with 5 mg/well of
DDR1 wild-type or mutant plasmid DNA using calcium phosphate precipita-
tion; 48 hr after transfection, the cells were dissociated with nonenzymatic
cell dissociation solution (Sigma) and resuspended in PBS containing 1%
BSA. The cells were incubated with primary mAb or mouse IgG1 isotype
control Ab (Cambridge Bioscience) at 10 mg/ml in 100 ml PBS/BSA for
30 min on ice, followed by three washes with PBS/BSA and incubation with
FITC-conjugated goat anti-mouse IgG (F-9006, Sigma) for 30 min on ice. After
three washes as above, the cells were resuspended in 2% formaldehyde in
PBS and analyzed on a FACSCalibur flow cytometer using Cell Quest Pro soft-
ware (Becton Dickinson Biosciences).
Crystal Structure Determination
The purified DDR1 protein for crystallography and the 3E3 Fab fragment were
mixed in an equimolar ratio and incubated on ice for 30 min. The solution was
subjected to size-exclusion chromatography on a Superdex 200 HR10/30
column (GE Healthcare) with TBS as the running buffer. The DDR1-3E3 Fab
complex was eluted as a single peak and was concentrated to 6mg/ml. Sitting
drop vapor diffusion crystallization screens were set up using a Mosquito
nanolitre robot (TTP LabTech). Crystals were obtained after 1–2 days at
room temperature using 2% Tacsimate (pH 5.0) (Hampton Research),
100 mM sodium citrate tribasic dihydrate (pH 5.6), and 20% PEG 3350 as
precipitant. Crystals were flash-frozen in liquid nitrogen after a brief soak in
mother liquor supplementedwith 25%glycerol. Diffraction datawere collected
at 100 K on station I02 at the Diamond Light Source (Oxfordshire, UK). The
data were processed with MOSFLM (www.mrc-lmb.cam.ac.uk/harry/
mosflm) and programs of the CCP4 suite (CCP4, 1994). The DDR1-3E3 Fab
structure was solved by molecular replacement with PHASER (McCoy et al.,
2007), using as search models the DDR2 DS domain (PDB entry 2wuh) and
a Fab fragment of an Ab directed against neuropilin-2 (PDB entry 2qqk). The
electron density map calculated from the correctly positioned search models
showed weak density for several b strands in the DS-like domain, which were
used to place the related coagulation factor V/VIII type C domain of galactose
oxidase (PDB entry 1k3i) as an aid for model building. The model was built with
O (Jones et al., 1991) and refined with CNS (Bru¨nger et al., 1998). Crystallo-
graphic statistics are summarized in Table 1. The figures were made with
PyMOL (http://www.pymol.org).
ACCESSION NUMBER
The coordinates of the DDR1-3E3 Fab structure have been deposited in the
Protein Data Bank (entry code 4ag4).
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